
Vicki L. Keedy, M.D., MSCI
- Associate Professor of Medicine (Hematology/Oncology)
- Clinical Director, Sarcoma
Phone
777 Preston Research Building
Nashville, TN 37232-6307
Vicki L. Keedy, M.D., MSCI
- Associate Professor of Medicine (Hematology/Oncology)
- Clinical Director, Sarcoma
615-936-3831
vicki.keedy@vumc.org
777 Preston Research Building
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Keedy is an Associate Professor of Medicine in the Division of Hematology/Oncology. After receiving her B.S. in Microbiology at Indiana University, she went to medical school at the University of Cincinnati. Dr. Keedy completed her Internal Medicine Residency and Hematology/Oncology training at Vanderbilt University Medical Center. She is a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.
Dr. Keedy is the Clinical Director for Sarcoma, a member of the Phase I Clinical Trial team, and serves as the principal investigator on several soft tissue sarcoma, bone sarcoma, GIST, and Phase I clinical trials. She is a member of the Sarcoma Alliance for Research Collaboration, and is a member of the AJCC Soft Tissue Sarcoma Expert Panel.
She is active in the American Society of Clinical Oncology, and has served on the Career Development and Health Services Committees. In her role as the Medical Director for the Clinical Trials Shared Resource, she serves on the AACI/Clinical Research Initiative working group.
Education
- University of Cincinnati College of Medicine, M.D.
- Residency/Fellowship: Vanderbilt University Medical Center
- Master of Science in Clinical Investigation, Vanderbilt University School of Medicine, 2009
Research Emphasis
Research Description
Publications
- Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. Oncologist [print-electronic]. 2015 Feb; 20(2): 105-6. PMID: 25616430, PMCID: PMC4319632, PII: theoncologist.2014-0327, DOI: 10.1634/theoncologist.2014-0327, ISSN: 1549-490X.
- Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA, Zamboni WC. Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors. Int J Nanomedicine. 2015; 10: 1201-9. PMID: 25709442, PMCID: PMC4334335, PII: ijn-10-1201, DOI: 10.2147/IJN.S62911, ISSN: 1178-2013.
- Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
- Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014 Apr; 9(4): 559-62. PMID: 24736081, PMCID: PMC3990869, PII: 01243894-201404000-00024, DOI: 10.1097/JTO.0000000000000079, ISSN: 1556-1380.
- Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. Case Rep Oncol Med [print-electronic]. 2014; 2014: 341980. PMID: 25328733, PMCID: PMC4190830, DOI: 10.1155/2014/341980, ISSN: 2090-6706.
- Cate F, Bridge JA, Crispens MA, Keedy VL, Troutman A, Coffin CM, Fadare O. Composite uterine neoplasm with embryonal rhabdomyosarcoma and primitive neuroectodermal tumor components: rhabdomyosarcoma with divergent differentiation, variant of primitive neuroectodermal tumor, or unique entity?. Hum. Pathol [print-electronic]. 2013 Apr; 44(4): 656-63. PMID: 23266445, PII: S0046-8177(12)00336-X, DOI: 10.1016/j.humpath.2012.09.008, ISSN: 1532-8392.
- Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol. 2013 Mar; 200(3): 475-83. PMID: 23436834, PMCID: PMC3652983, PII: 200/3/475, DOI: 10.2214/AJR.12.9049, ISSN: 1546-3141.
- Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer [print-electronic]. 2013 Jan; 14(1): 14-8. PMID: 22591607, PII: S1525-7304(12)00075-7, DOI: 10.1016/j.cllc.2012.03.008, ISSN: 1938-0690.
- Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-ß, COX2 and sex steroid receptors. Cancer Sci [print-electronic]. 2012 Dec; 103(12): 2173-80. PMID: 23035734, PMCID: PMC4278584, DOI: 10.1111/cas.12037, ISSN: 1349-7006.
- Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM. Nuclear p63 expression in osteoblastic tumors. Tumour Biol [print-electronic]. 2012 Oct; 33(5): 1639-44. PMID: 22623071, DOI: 10.1007/s13277-012-0419-y, ISSN: 1423-0380.
- Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Hum. Pathol [print-electronic]. 2012 Oct; 43(10): 1711-8. PMID: 22520949, PMCID: PMC4278590, PII: S0046-8177(11)00530-2, DOI: 10.1016/j.humpath.2011.12.021, ISSN: 1532-8392.